Abstract: A lighting device for a motor vehicle, wherein the lighting device has a circuit board with a multiplicity of light-emitting diodes arranged thereon, a transparent optical layer, and a reflector element, wherein the reflector element is arranged between the circuit board and the optical layer, wherein the reflector element has multiple segments into which the reflector element is subdivided, wherein a segment is associated with each light-emitting diode so that light emitted by the light-emitting diodes can be reflected by the reflector element and can pass through the optical layer. Two light-emitting diodes are arranged in a segment. In addition, a lighting system and a motor vehicle are provided.

Abstract: A lighting device for a vehicle, having a plurality of light sources, which are arranged in an array, in particular in line-by-line and column-by-column fashion, and can be operated independently of each other at least in part, wherein the light sources emit light during operation; an exit face through which the light emanating from the light sources passes; and a plurality of extensive boundary elements, which extend at least partly in a region between the light sources and the exit face and serve to separate the light emanating from different light sources, wherein at least some, preferably all, of the extensive boundary elements have a reflector which at least partly reflects the light emanating from one of the light sources in the direction of the exit face.

Abstract: A method for tracking extended objects in the surroundings of a vehicle includes the steps of: (a) providing modeled components for an object; (b) determining a detection from sensor data; and (c) determining the origin of the detection on the object using the modeled components. The process of determining the origin of the detection on the object includes determining association probabilities for the plurality of modeled components, in which the association probabilities indicate the degree of probability with which the detection is associated with the individual components of the modeled components.

Abstract: Described herein are compounds comprising a dimer of dehydrosalicortin or a derivative, homologue, stereoisomer, prodrug or pharmaceutical salt thereof. In particular embodiments, the dimer is a result of a Diels-Alder reaction. Also described are compositions comprising the compounds and their use in treating disease.

Abstract: Methods for alleviating pain comprising administering to a subject sphingosine-1-phosphate, functional fragments and derivatives thereof, and other compounds, and assays for identifying such compounds.

Abstract: The invention relates to a condensation product obtainable by reaction of a1) at least one bicyclic or polycyclic aromatic or heteroaromatic, where the bicyclic or polycyclic aromatic or heteroaromatic is substituted by at least one carboxyl group (—COOH), and where the carboxyl group can be present in salt form, a2) at least one carbonyl compound, a3) if appropriate at least one sulfonating agent, a4) at least one urea derivative, and a5) if appropriate at least one further aromatic or heteroaromatic, or a physiologically tolerable salt thereof.

Abstract: The present invention relates to a method of identifying a compound involved in pain, the use of Ctla2b nucleic acid or Ctla2b protein for identifying a compound involved in pain as well as methods of diagnosing algesia involving the same.

Abstract: The present invention relates to the use of I?B-kinase Inhibitors and methods for the prophylaxis and therapy for treating pain comprising administering such compounds.

Abstract: The present invention relates to a method of identifying a compound involved in pain, the use of Epsti1 nucleic acid or Epsti1 protein for identifying a compound involved in pain as well as methods of diagnosing algesia involving the same.

Abstract: The present invention relates to a method of identifying a compound involved in pain, the use of Ms4a6d nucleic acid or Ms4a6d protein for identifying a compound involved in pain as well as methods of diagnosing algesia involving the same.

Abstract: The present invention relates to the use of sulfonyl-substituted 2-sulfonylaminobenzoic acid N-phenylamides of the formula I, wherein A and R1 to R6 have the meanings indicated in the claims, for treating pain and for manufacturing a medicament for the treatment of pain.

Abstract: The present invention relates to a method of identifying a compound involved in pain, the use of Car3 nucleic acid or Car3 protein for identifying a compound involved in pain as well as methods of diagnosing algesia involving the same.

Abstract: The present invention relates to a method of identifying a compound involved in pain, the use of Ctla2b nucleic acid or Ctla2b protein for identifying a compound involved in pain as well as methods of diagnosing algesia involving the same.

Abstract: The present invention relates to a method of identifying a compound involved in pain, the use of Epsti1 nucleic acid or Epsti1 protein for identifying a compound involved in pain as well as methods of diagnosing algesia involving the same.

Abstract: The present invention relates to a method of identifying a compound involved in pain, the use of Ifi205 nucleic acid or Ifi205 protein for identifying a compound involved in pain as well as methods of diagnosing algesia involving the same.

Abstract: The present invention relates to a method of identifying a compound involved in pain, the use of Il2rg nucleic acid or Il2rg protein for identifying a compound involved in pain as well as methods of diagnosing algesia involving the same.

Abstract: Present invention concerns the use of Cathepsin C. Other aspects of the invention concern methods for screening pharmaceuticals, for diagnosing pain susceptibility and for the treatment of pain.

Abstract: The present invention relates to a method of identifying a compound involved in pain, the use of C1qb nucleic acid or C1qb protein for identifying a compound involved in pain as well as methods of diagnosing algesia involving the same.

Abstract: The invention relates to anti-integrin antibodies which are covalently linked to nanoparticles, wherein these nanoparticles were prior loaded with chemotherapeutic/cytotoxic agents. The antibody-chemotherapeutic agent-nanoparticle conjugates according to the invention, especially wherein the antibody is MAb DI17E6 and the cytotoxic agent is doxorubicin show a significant increase of tumor cell toxicity.

Abstract: Present invention concerns the use of Cathepsin H. Other aspects of the invention concern methods for screening pharmaceuticals, for diagnosing pain susceptibility and for the treatment of pain.